MCID: INT025
MIFTS: 35

Intermittent Explosive Disorder malady

Category: Mental diseases

Aliases & Classifications for Intermittent Explosive Disorder

About this section

Aliases & Descriptions for Intermittent Explosive Disorder:

Name: Intermittent Explosive Disorder 11 13 66
 
Explosive Personality Disorder 11 66

Classifications:



External Ids:

Disease Ontology11 DOID:12401
ICD1028 F60.3, F63.81
ICD9CM30 301.3, 312.34
MeSH37 D007174
NCIt43 C94332

Summaries for Intermittent Explosive Disorder

About this section
Disease Ontology:11 An impulse control disorder that involves the episodic inability to control violent impulses with a disproportionate degree of aggressiveness.

MalaCards based summary: Intermittent Explosive Disorder, also known as explosive personality disorder, is related to obsessive-compulsive personality disorder and pyromania. An important gene associated with Intermittent Explosive Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways are Sympathetic Nerve Pathway (Neuroeffector Junction) and G alpha (s) signalling events. Affiliated tissues include amygdala and brain.

Wikipedia:69 Intermittent explosive disorder (sometimes abbreviated as IED) is a behavioral disorder characterized by... more...

Related Diseases for Intermittent Explosive Disorder

About this section

Diseases related to Intermittent Explosive Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 69)
idRelated DiseaseScoreTop Affiliating Genes
1obsessive-compulsive personality disorder30.3HTR1A, HTR1B, SLC6A4
2pyromania30.2HTR1A, HTR7, SLC6A4
3avoidant personality disorder29.9HTR1A, HTR7, SLC6A4
4paranoid personality disorder10.6HTR1A, SMOC1
5idiopathic neonatal atrial flutter10.6HTR1A, SLC6A4
6dyserythropoietic anemia, congenital, type iii10.6CHRFAM7A, CHRNA7
7nonencapsulated sclerosing carcinoma10.6HTR1A, SLC6A4
8central sleep apnea10.5HTR1A, SLC6A4
9malignant peripheral nerve sheath tumor10.4HTR1A, SLC6A4
10lymphocytic colitis10.4IL6, SLC6A4
11intrahepatic gall duct cancer10.4HTR7, SLC6A4
12dental fluorosis10.3HTR1A, HTR1B, SLC6A4
13aneurysm of sinus of valsalva10.3CRP, IL6
14chronic cervicitis10.3HTR1A, HTR1B, SLC6A4
15panner disease10.3CRP, IL6
16carbon baby syndrome10.3CRP, IL6
17atrophic vulva10.3CRP, IL6
18angioma hereditary neurocutaneous10.3CRP, IL6
19midline interhemispheric variant of holoprosencephaly10.2CRP, IL6
20epstein-barr virus hepatitis10.2CRP, IL6
21malignant gastric granular cell tumor10.2CRP, IL6
22aicardi-goutieres syndrome 210.2HTR1A, HTR1B, SLC6A4
23chronic diarrhea due to guanylate cyclase 2c overactivity10.2CRP, IL6
24conventional leiomyosarcoma10.2CRP, IL6
25anosognosia10.2CRP, HTR1A, SLC6A4
26cyclothymic disorder10.2CRP, IL6
27queensland tick typhus10.2CRP, IL6
28opiate dependence10.2CRP, IL6
29renal cell carcinoma 410.2CHRNA7, IL6
30lung occult adenocarcinoma10.2CRP, IL6
31personality disorder10.1
32antidepressant type abuse10.1CRP, IL6
33substernal goiter10.1CRP, IL6
34pyoderma gangrenosum10.1HTR1A, IL6, SLC6A4
35pulmonary tuberculosis10.1HTR1A, HTR7
36diabetic encephalopathy10.1CRP, IL6, SLC6A4
37colon lymphoma10.1CRP, IL6, SMOC1
38periampullary adenoma10.1CRP, IL6, SLC6A4
39islet cell tumor10.1CRP, IL6
40ovarian primitive germ cell tumor10.1CRP, IL6, SMOC1
41vernal conjunctivitis10.1CHRFAM7A, CHRNA7, HTR1A, SLC6A4
42conjunctival degeneration10.1HTR1A, HTR7, SLC6A4
43idiopathic neutropenia10.0CRP, IL6
44hypoglycemic coma10.0HTR1A, HTR7, SLC6A4
45aphthous stomatitis10.0ADRB1, CRP, IL6
46gastric body carcinoma10.0HTR1B, HTR7
47craniosynostosis9.9ADRB1, CRP, IL6
48paraneoplastic polyneuropathy9.9CRP, IL6
49sudden infant death syndrome9.9HTR1A, IL6, SLC6A4
50pervasive developmental disorder9.9HTR7, MFAP4, SLC6A4

Comorbidity relations with Intermittent Explosive Disorder via Phenotypic Disease Network (PDN):


Acute CystitisAlzheimer Disease
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Intermittent Explosive Disorder:



Diseases related to intermittent explosive disorder

Symptoms for Intermittent Explosive Disorder

About this section

Drugs & Therapeutics for Intermittent Explosive Disorder

About this section

Drugs for Intermittent Explosive Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 6)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
SerotoninPhase 4, Phase 3, Phase 2351050-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
2
GuanfacinePhase 45629110-47-23519
Synonyms:
29110-47-2
29110-48-3 (mono-hydrochloride)
AC1L1G4B
BPBio1_000415
BRD-K32830106-003-03-0
BSPBio_000377
C07037
C9H9Cl2N3O
CAS-29110-48-3
CHEMBL862
CID3519
D08031
DB01018
EINECS 249-442-8
Estulic
Estulic (TN)
G1043_SIGMA
GUANFACINE
Guanfacina
Guanfacina [INN-Spanish]
Guanfacine (INN)
Guanfacine Monohydrochloride
Guanfacine [INN:BAN]
Guanfacinum
 
Guanfacinum [INN-Latin]
Intuniv
L000286
L013430
LS-174236
Lon798
Lopac-G-1043
Lopac0_000519
MolPort-003-941-447
N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
NCGC00015469-01
NCGC00015469-02
NCGC00015469-06
NCGC00024950-01
NCGC00024950-02
NCGC00024950-03
Prestwick0_000339
Prestwick1_000339
Prestwick2_000339
Prestwick3_000339
SPBio_002298
SPD 503
Tocris-1030
UNII-30OMY4G3MK
ZINC03872738
3
NaratriptanPhase 414143388-64-1, 121679-13-84440
Synonyms:
121679-13-8
AC-5013
AC1L1I6A
Amerge, Naramig,Naratriptan
BIDD:GT0312
C07792
CHEBI:7478
CHEMBL1278
CID4440
Colatan
D08255
DB00952
InChI=1/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H
L000432
 
LS-83062
MolPort-005-932-823
N-Methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide
N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide
N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide
NCGC00181786-01
Naramig
Naramig (TN)
Naratriptan (INN)
Naratriptanum
S1488_Selleck
UNII-QX3KXL1ZA2
naratriptan
naratriptanum
4
RisperidonePhase 3482106266-06-25073
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
BIDD:GT0262
BRD-K53857191-001-04-5
BRN 4891881
Belivon
Bio-0092
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
CPD000466323
Consta, Risperdal
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
LS-134196
Lopac-R-118
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
 
NCGC00015883-01
NCGC00015883-02
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R-64,766
R-64-766
R-64766
R64,766
R64766
Rispen
Risperdal
Risperdal (TN)
Risperdal Consta
Risperdal M-Tab
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
Risperidone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
SMR000466323
SPBio_003078
STK646402
Sequinan
Spiron
TL8000230
UNII-L6UH7ZF8HC
risperdone
risperidone
5
DopaminePhase 3367851-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
6
FluoxetinePhase 222954910-89-33386
Synonyms:
(+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+/-)-Fluoxetine
(+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine
(+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]
(+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine
3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
52341-67-0
54910-89-3
57226-07-0
59333-67-4 (hydrochloride)
AB00053774
AC-14564
AC1L1FTH
AKOS003663021
Adofen
Animex-On
BPBio1_000354
BPBio1_000509
BRD-A31159102-001-01-9
BRD-A31159102-003-05-6
BSPBio_000461
BSPBio_003375
Bio-0787
Biomol-NT_000152
C17H18F3NO
CHEBI:5118
CHEMBL41
CID3386
D00326
DB00472
Deprex
DivK1c_006819
Eufor
Floxetine
Fluctin
Fluoxeren
Fluoxetin
Fluoxetina
Fluoxetina [INN-Spanish]
Fluoxetina [Spanish]
Fluoxetine (TN)
Fluoxetine (USAN/INN)
Fluoxetine Hcl
Fluoxetine Hydrochloride
Fluoxetine [USAN:INN:BAN]
Fluoxetinum
 
Fluoxetinum [INN-Latin]
Fluoxétine
Fluval
Fontex
Foxetin
HMS2090H14
KBio1_001763
KBio2_002159
KBio2_004727
KBio2_007295
KBio3_002595
KBioGR_001166
KBioSS_002159
L000931
LS-31040
Lilly-110140
Lopac0_000558
Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine
Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine
MolPort-001-683-482
N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine
NCGC00015428-10
NCGC00024879-03
NCGC00024879-04
NSC283480
Portal
Prestwick0_000511
Prestwick1_000511
Prestwick2_000511
Prestwick3_000511
Prozac
Prozac Weekly
Pulvules
Reconcile
Reneuron
SPBio_001815
SPBio_002382
STK734483
Sarafem
SpecPlus_000723
Spectrum2_001658
Spectrum3_001648
Spectrum4_000613
Spectrum5_001518
Spectrum_001679
TL8003595
UNII-01K63SUP8D
dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
fluoxetine
fluoxetine (Prozac)
nchembio.534-comp2

Interventional clinical trials:

idNameStatusNCT IDPhase
1Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive DisorderRecruitingNCT02048241Phase 4
2Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment OrderTerminatedNCT00282165Phase 4
3Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.CompletedNCT00399698Phase 3
4Psychotherapy for Intermittent Explosive DisorderCompletedNCT00667212Phase 2
5Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive DisorderCompletedNCT02055638Phase 1, Phase 2
6A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive DisorderCompletedNCT00078754Phase 2
7A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With IEDCompletedNCT00127400Phase 2

Search NIH Clinical Center for Intermittent Explosive Disorder

Genetic Tests for Intermittent Explosive Disorder

About this section

Anatomical Context for Intermittent Explosive Disorder

About this section

MalaCards organs/tissues related to Intermittent Explosive Disorder:

34
Amygdala, Brain

Animal Models for Intermittent Explosive Disorder or affiliated genes

About this section

Publications for Intermittent Explosive Disorder

About this section

Articles related to Intermittent Explosive Disorder:

(show top 50)    (show all 80)
idTitleAuthorsYear
1
Prevalence of DSM-IV Intermittent Explosive Disorder in Black Adolescents: Findings From the National Survey of American Life, Adolescent Supplement. (27078052)
2016
2
Comorbid intermittent explosive disorder and posttraumatic stress disorder: Clinical correlates and relationship to suicidal behavior. (27624432)
2016
3
White Matter Integrity Reductions in Intermittent Explosive Disorder. (27206265)
2016
4
Social cognition in Intermittent Explosive Disorder and aggression. (27621104)
2016
5
Single Case Study: Neuropsychological Functioning in a Patient Diagnosed with Intermittent Explosive Disorder Pre and Post Neurosurgery. (27161981)
2016
6
Defense styles in Intermittent Explosive Disorder. (27086223)
2016
7
Negative urgency and reward/punishment sensitivity in intermittent explosive disorder. (27155024)
2016
8
Amygdala hyperactivation to angry faces in intermittent explosive disorder. (27145325)
2016
9
Verbal versus physical aggression in Intermittent Explosive Disorder. (25534757)
2015
10
Emotion regulation deficits in intermittent explosive disorder. (27539871)
2015
11
Emotional intelligence and impulsive aggression in Intermittent Explosive Disorder. (25477263)
2015
12
The experience of aggressive outbursts in Intermittent Explosive Disorder. (25541537)
2015
13
Inflammatory markers and chronic exposure to fluoxetine, divalproex, and placebo in intermittent explosive disorder. (26277033)
2015
14
Self-harm behavior among individuals with intermittent explosive disorder and personality disorders. (25300440)
2014
15
Relationship between psychopathy, aggression, anger, impulsivity, and intermittent explosive disorder. (24760575)
2014
16
Validity of the new A1 and A2 criteria for DSM-5 intermittent explosive disorder. (24321204)
2014
17
Intermittent Explosive Disorder and aversive parental care. (25064384)
2014
18
History of childhood maltreatment in intermittent explosive disorder and suicidal behavior. (24935900)
2014
19
Doing Psychiatry Right: A Case of Severe Avoidant Personality Disorder with Obsessive-compulsive Personality Disorder, Obsessive Compulsive Disorder, Intermittent Explosive Disorder and Sexual Paraphilias. (25035563)
2014
20
Emotion regulation deficits in intermittent explosive disorder. (25403171)
2014
21
Intermittent explosive disorder: associations with PTSD and other Axis I disorders in a US military veteran sample. (24907536)
2014
22
Common and distinct neural correlates of inhibitory dysregulation: stroop fMRI study of cocaine addiction and intermittent explosive disorder. (25106072)
2014
23
Achieving convergence between a community-based measure of explosive anger and a clinical interview for intermittent explosive disorder in Timor-Leste. (23835102)
2013
24
Elevated Plasma Inflammatory Markers in Individuals With Intermittent Explosive Disorder and Correlation With Aggression in Humans. (24352431)
2013
25
Intermittent explosive disorder in the National Comorbidity Survey Replication Adolescent Supplement. (22752056)
2012
26
Striatal activity in borderline personality disorder with comorbid intermittent explosive disorder: sex differences. (22464337)
2012
27
A case of intermittent explosive disorder. (21694793)
2010
28
Expert witness claimed that a defendant had "intermittent explosive disorder," GMC hears. (21147742)
2010
29
Deep brain stimulation of the orbitofrontal projections for the treatment of intermittent explosive disorder. (20672913)
2010
30
Unhealthy aggression: intermittent explosive disorder and adverse physical health outcomes. (20496987)
2010
31
Latent structure of intermittent explosive disorder in an epidemiological sample. (20064645)
2010
32
A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. (19389333)
2009
33
P3a and mismatch negativity in individuals with moderate Intermittent Explosive Disorder. (19463896)
2009
34
Prevalence of suicidal and self-injurious behavior among subjects with intermittent explosive disorder. (18221794)
2008
35
The relationship between impulsive verbal aggression and intermittent explosive disorder. (17654692)
2008
36
Intranasal ketamine for intermittent explosive disorder: a case report. (17854260)
2007
37
Intermittent explosive disorder-integrated research diagnostic criteria: convergent and discriminant validity. (16153657)
2006
38
Intermittent explosive disorder. (17131536)
2006
39
Prevalence and features of intermittent explosive disorder in a clinical setting. (16259534)
2005
40
Intermittent explosive disorder and impulsive aggression: the time for serious study is now. (14738696)
2004
41
Lifetime and 1-month prevalence rates of intermittent explosive disorder in a community sample. (15291659)
2004
42
Intermittent explosive disorder and other psychiatric comorbidity among court-referred and self-referred aggressive drivers. (12051483)
2002
43
Intermittent explosive disorder: epidemiology, diagnosis and management. (12096933)
2002
44
Validation of the Interview Module for Intermittent Explosive Disorder (M-IED) in children and adolescents: a pilot study. (11311929)
2001
45
Intermittent explosive disorder. (11122935)
2000
46
DSM-IV intermittent explosive disorder: a report of 27 cases. (9590677)
1998
47
The diagnosis of intermittent explosive disorder in violent men. (2039850)
1991
48
Carbamazepine for intermittent explosive disorder in a Prader-Willi syndrome patient. (3667542)
1987
49
Therapeutic use of propranolol for intermittent explosive disorder. (3546964)
1987
50
Metoprolol for intermittent explosive disorder. (4025634)
1985

Variations for Intermittent Explosive Disorder

About this section

Expression for genes affiliated with Intermittent Explosive Disorder

About this section
Search GEO for disease gene expression data for Intermittent Explosive Disorder.

Pathways for genes affiliated with Intermittent Explosive Disorder

About this section

Pathways related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.3ADRB1, NPY
29.3ADRB1, CGA, HTR7
38.8HTR1A, HTR1B, HTR7, SLC6A4
4
Show member pathways
8.7ADRB1, HTR1A, HTR1B, HTR7
58.7CHRFAM7A, CHRNA7, HTR1A, IL6, SLC6A4
6
Show member pathways
8.5ADRB1, HTR1A, HTR1B, NPY
7
Show member pathways
8.5CHRNA7, HTR1A, HTR1B, HTR7, SLC6A4
8
Show member pathways
7.3ADRB1, CGA, CHRNA7, HTR1A, HTR1B, HTR7

GO Terms for genes affiliated with Intermittent Explosive Disorder

About this section

Biological processes related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of organ growthGO:004662110.5CGA, SLC6A4
2adenylate cyclase-inhibiting serotonin receptor signaling pathwayGO:000719810.4HTR1A, HTR1B
3regulation of behaviorGO:005079510.3HTR1A, HTR1B
4bone remodelingGO:004684910.2HTR1B, IL6
5serotonin receptor signaling pathwayGO:000721010.0HTR1A, HTR7
6negative regulation of lipid storageGO:00108889.9CRP, IL6
7vasoconstrictionGO:00423109.4HTR1A, HTR1B, HTR7, SLC6A4
8positive regulation of gene expressionGO:00106289.1CRP, CTSH, IL6, SLC6A4
9G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerGO:00071878.7HTR1B, HTR7, NPY
10chemical synaptic transmissionGO:00072688.4HTR1B, HTR7, NPY, SLC6A4
11positive regulation of cell proliferationGO:00082848.4CGA, CHRNA7, CTSH, HTR1A, IL6

Molecular functions related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1G-protein coupled serotonin receptor activityGO:00049939.1HTR1A, HTR1B, HTR7

Sources for Intermittent Explosive Disorder

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet